NEW YORK (GenomeWeb) – MDx firm Diacarta shared new data today on the use of its colorectal cancer mutation assay in analyzing blood samples of patients with early-stage colorectal cancer, positioning the kit as a liquid biopsy tool.
The firm could potentially compete with or enhance other amplification-based systems that are increasingly being explored and adopted into clinical practice.
Researchers shared the data in an abstract at the American Association for Cancer Research’s International Conference on Molecular Targets and Cancer Therapeutics this morning, reporting that their technology successfully detected circulating cancer mutations in 92 percent of cases across a range of cancer stages.
ColoScape is already CE marked as of February this year, but DiaCarta CSO Michael Powell said that the firm has been marketing it mainly for FFPE tissue samples so far.
Elena Peletskaya, DiaCarta’s director of diagnostics, added that the plan is to begin promoting the kits for both tissue and plasma very soon.
“We already have the studies and documentation available, it’s just figuring out the best time to announce it,” she said.
Since the first US Food and Drug Administration approval of a liquid biopsy assay — Roche’s cobas EGFR Mutation Test — last year, diagnostics